The UK NHS approves Atogepant (Aquipta) pill for migraines, benefiting ~170,000 patients.
The National Health Service (NHS) in the UK has approved Atogepant, a new daily pill for chronic and episodic migraines, benefiting around 170,000 sufferers. The drug, sold under the brand name Aquipta and manufactured by AbbVie, provides patients with an oral treatment option instead of injectables. Atogepant blocks the receptor of a protein called calcitonin gene-related peptide (CGRP), found in the sensory nerves of the head and neck, which dilates blood vessels and leads to inflammation and migraines. The drug is now available on the NHS for patients with at least four migraine days a month who have already tried and found ineffective at least three other treatments.
April 11, 2024
22 Articles